Jonathan Hogan
Columbia University Medical Center
11 Papers
144 Citations
Jonathan Hogan is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Membranous nephropathy & Minimal change disease. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
The Treatment of Minimal Change Disease in Adults
Jonathan Hogan,Jai Radhakrishnan +1 more
TL;DR: MCD in adults is reviewed with particular focus on the evidence for immunosuppressive therapy in patients with recurrent relapses, and some patients become steroid-resistant (SR), steroid-dependent (SD), or frequently relapsing (FR).
151
Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.
Jonathan Hogan,Andrew S. Bomback,Kshama R. Mehta,Pietro A. Canetta,Maya K. Rao,Gerald B. Appel,Jai Radhakrishnan,Richard A. Lafayette +7 more
TL;DR: Responsibility to ACTH treatment among steroid-resistant or steroid-dependent patients with FSGS is low, but ACTH gel may be a viable treatment option for some patients with resistant nephrotic syndrome due to idiopathic FSGS.
96
Rituximab treatment for fibrillary glomerulonephritis
Jonathan Hogan,Michaela D. Restivo,Pietro A. Canetta,Leal Herlitz,Jai Radhakrishnan,Gerald B. Appel,Andrew S. Bomback +6 more
TL;DR: Rituximab therapy was associated with non-progression of renal disease in 4 of 12 patients and at the time of treatment, these non-progressors had better renal function and shorter time from diagnosis to treatment than progressors.
Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis
TL;DR: Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, as well as available measures to prevent such events, when choosing the ideal regimen for an individual patient.
The Treatment of Idiopathic Focal Segmental Glomerulosclerosis in Adults
Jonathan Hogan,Jai Radhakrishnan +1 more
TL;DR: First-line treatment for idiopathic FSGS patients with nephrotic-range proteinuria is a prolonged course of corticosteroids, however, steroid resistance is common and portends an increased risk of long-term decline in kidney function and end-stage kidney disease in these patients compared with responders.
24